Prelude Capital Management LLC Takes $314,000 Position in Catalent, Inc. (NYSE:CTLT)

Prelude Capital Management LLC bought a new position in shares of Catalent, Inc. (NYSE:CTLT) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,782 shares of the company’s stock, valued at approximately $314,000.

A number of other large investors have also bought and sold shares of CTLT. KB Financial Partners LLC acquired a new position in Catalent during the 1st quarter worth approximately $30,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Catalent during the fourth quarter worth approximately $34,000. FNY Investment Advisers LLC bought a new position in shares of Catalent in the 1st quarter worth $34,000. Optiver Holding B.V. acquired a new stake in Catalent in the 1st quarter valued at $35,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new stake in Catalent during the 1st quarter valued at $48,000.

Insider Buying and Selling at Catalent

In related news, CEO Alessandro Maselli sold 1,485 shares of Catalent stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $47.13, for a total value of $69,988.05. Following the completion of the sale, the chief executive officer now owns 86,101 shares of the company’s stock, valued at approximately $4,057,940.13. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Alessandro Maselli sold 1,485 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $47.13, for a total value of $69,988.05. Following the completion of the transaction, the chief executive officer now directly owns 86,101 shares of the company’s stock, valued at approximately $4,057,940.13. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John J. Greisch bought 21,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $50.24 per share, for a total transaction of $1,055,040.00. Following the transaction, the insider now owns 34,000 shares of the company’s stock, valued at $1,708,160. The disclosure for this purchase can be found here. Insiders have sold a total of 5,442 shares of company stock worth $247,577 over the last ninety days. 0.58% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CTLT has been the topic of a number of recent research reports. Wells Fargo & Company initiated coverage on shares of Catalent in a research note on Thursday, July 20th. They issued an “equal weight” rating and a $43.00 price objective on the stock. Royal Bank of Canada lifted their price target on Catalent from $51.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday, August 30th. Morgan Stanley increased their price objective on Catalent from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 30th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Wednesday, August 30th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Catalent from $37.00 to $45.00 and gave the company a “hold” rating in a research report on Tuesday, August 15th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $53.58.

Catalent Price Performance

CTLT opened at $49.16 on Monday. The firm has a market cap of $8.86 billion, a P/E ratio of -37.82, a PEG ratio of 3.85 and a beta of 1.23. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.27 and a current ratio of 1.78. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $90.81. The firm has a 50-day moving average of $47.05 and a 200 day moving average of $48.85.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, August 29th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Catalent had a negative net margin of 5.43% and a positive return on equity of 3.24%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the prior year, the company earned $1.12 earnings per share. The firm’s revenue was down 15.6% on a year-over-year basis. On average, research analysts expect that Catalent, Inc. will post 0.7 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.